Literature DB >> 19564720

Growth hormone response to physical exercise in growing patients with classic congenital adrenal hyperplasia.

C Bizzarri1, G Ubertini, F Crea, D Colabianchi, S Loche, L Ravà, M Cappa.   

Abstract

Glucocorticoid over-treatment in children with congenital adrenal hyperplasia (CAH) may suppress GH secretion and growth. Aims of our study were: 1) to evaluate post-exercise GH response in patients affected by CAH due to 21-hydroxylase deficiency, in comparison with a group of healthy subjects; 2) to investigate the relationship between the hormonal markers of adequate steroid therapy and GH secretion. We evaluated GH secretion every 6 months in 20 young CAH patients (8 girls, 12 boys). Mean follow-up was 4.6+/-0.9 yr (107 tests performed, 5.35+/-2.05 repeated tests for each patient). Forty-four healthy subjects (25 boys, 19 girls) were selected as a control group. The range of post-exercise GH peak was very wide, but medians were not statistically different in cases and controls (p=0.570). Multivariate analysis showed that post-exercise GH peak was not related to age (p=0.743), gender (p=0.296) or pubertal status (p=0.440) in both groups. GH increase from baseline showed the same behavior (p=0.265, 0.639 and 0.105, respectively). In CAH patients, GH peak and GH increase were both directly related to 17-OH-progesterone levels [GH peak: p=0.032--95% confidence interval (CI): 0.01-0.34--beta=0.18; GH increase: p=0.008--95% CI: 0.06-0.35--beta=0.20]. The negative effect of glucocorticoid therapy on GH secretion seems to be dominant in CAH. The most effective approach to adjust treatment remains monitoring growth. Relying on hormonal markers to adequate steroid therapy may result in over-treatment, GH suppression, and finally poor linear growth.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19564720     DOI: 10.1007/BF03345770

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  Growth hormone deficiency in salt-losing congenital adrenal hyperplasia.

Authors:  Antonina Tirendi; Cristina Traggiai; Gerald S Conway; Richard Stanhope
Journal:  Eur J Pediatr       Date:  2002-08-28       Impact factor: 3.183

2.  Variations in pattern of pubertal changes in girls.

Authors:  W A Marshall; J M Tanner
Journal:  Arch Dis Child       Date:  1969-06       Impact factor: 3.791

3.  Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children.

Authors:  E Ghigo; J Bellone; G Aimaretti; S Bellone; S Loche; M Cappa; E Bartolotta; F Dammacco; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

4.  Oral hydrocortisone administration in children with classic 21-hydroxylase deficiency leads to more synchronous joint GH and cortisol secretion.

Authors:  Evangelia Charmandari; Steven M Pincus; David R Matthews; Atholl Johnston; Charles G D Brook; Peter C Hindmarsh
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

Review 5.  Mechanisms of steroid impairment of growth.

Authors:  Ze'ev Hochberg
Journal:  Horm Res       Date:  2002

6.  Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocorticoid replacement.

Authors:  A Giustina; G Romanelli; R Candrina; G Giustina
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

7.  A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo.

Authors:  N A Huizenga; J W Koper; P De Lange; H A Pols; R P Stolk; H Burger; D E Grobbee; A O Brinkmann; F H De Jong; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1998-01       Impact factor: 5.958

8.  [Corticosteroid treatment regimes and growth hormone secretion in congenital adrenogenital syndrome].

Authors:  A Balsamo; A Cicognani; P Guacci; A Cassio; E Cacciari
Journal:  Pediatr Med Chir       Date:  1993 Nov-Dec

9.  Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty.

Authors:  Nike M M L Stikkelbroeck; Bep A E Van't Hof-Grootenboer; Ad R M M Hermus; Barto J Otten; Martin A Van't Hof
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

Review 10.  Growth in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Helmuth G Dörr
Journal:  Horm Res       Date:  2007-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.